Pediatric Hematology and Oncology最新文献

Intrathecal chemotherapy neurotoxicity: unveiling the challenges of diagnosis, management, and prevention.

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2025-03-20 DOI: 10.1080/08880018.2025.2471098

Ali H Algiraigri, Wasil Jastaniah

引用次数: 0

Environmental health disparities in pediatric cancer: a report from the Fourth Symposium on Childhood Cancer Health Disparities.

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2025-03-20 DOI: 10.1080/08880018.2025.2479479

Thanh T Hoang, Zdenko Herceg, Don W Coulter, Adam de Smith, Manish Arora, William E Funk, David Haynes, Stephen H Linder, Leticia M Nogueira, Amy E Hughes, Lindsay A Williams, Jeremy M Schraw, Michael E Scheurer, Philip J Lupo

引用次数: 0

Primary gonadal failure in children with intracranial brain tumors treated with high dose alkylating agents and radiation sparing therapy: an institutional case series.

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2025-03-20 DOI: 10.1080/08880018.2025.2480741

Sylvia Cheng, Sarah Riedlinger, Rebecca Ronsley, Laura Stewart, Juliette Hukin, Carol K L Lam

{"title":"Primary gonadal failure in children with intracranial brain tumors treated with high dose alkylating agents and radiation sparing therapy: an institutional case series.","authors":"Sylvia Cheng, Sarah Riedlinger, Rebecca Ronsley, Laura Stewart, Juliette Hukin, Carol K L Lam","doi":"10.1080/08880018.2025.2480741","DOIUrl":"https://doi.org/10.1080/08880018.2025.2480741","url":null,"abstract":"Treatment of young children with brain tumors may require the use of high dose chemotherapy with alkylating agents to avoid craniospinal irradiation. The objective of this study is to describe the probability of primary gonadal failure (PGF) in children with a malignant intracranial tumor treated with high-dose alkylating agents in children diagnosed less than age 8 years who were treated with this radiation-sparing approach at our institution. Patient demographics, oncological and endocrine diagnoses, treatment modalities, and laboratory values were collected. Descriptive statistics, Kaplan Meier survival curves, regression analysis, and T-tests were used in data analysis. Eight of 18 (44%) developed PGF. The probability of developing PGF is 11% at 5 years, and 31% at 10 years. Cyclophosphamide equivalent dose (CED) was higher and duration of follow-up was longer in children with PGF. PGF is common in children who received CED without irradiation, but further studies are needed to correlate CED dose and time to onset of PGF.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"1-8"},"PeriodicalIF":1.2,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Child self-regulation and caregiver hope: insights from families navigating Sickle cell disease and pediatric cancer.

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2025-03-20 DOI: 10.1080/08880018.2025.2480223

James Rujimora, Amanda C DeDiego

引用次数: 0

Response to neoadjuvant selpercatinib in a pediatric patient with advanced papillary thyroid carcinoma: a case report.

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2025-03-03 DOI: 10.1080/08880018.2025.2466022

Taylor Luckie, Daniel Chelius, Amy Dimachkieh, Norma Quintanilla, Angshumoy Roy, Andrew C Sher, Priya Mahajan

引用次数: 0

Vitamin D deficiency in a pediatric population with sickle cell disease. 镰状细胞病儿童人群的维生素D缺乏症

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-17 DOI: 10.1080/08880018.2025.2451843

Thiago de Souza Vilela, Mauro Fisberg, Gerson Ferrari, Josefina Aparecida Pellegrini Braga

{"title":"Vitamin D deficiency in a pediatric population with sickle cell disease.","authors":"Thiago de Souza Vilela, Mauro Fisberg, Gerson Ferrari, Josefina Aparecida Pellegrini Braga","doi":"10.1080/08880018.2025.2451843","DOIUrl":"10.1080/08880018.2025.2451843","url":null,"abstract":"Pediatric patients with sickle cell disease and vitamin D deficiency have worse clinical and laboratory outcomes. This study aims to quantify the prevalence of vitamin D deficiency in this population and identify possible risk factors for hypovitaminosis D by performing a cross-sectional study with children aged 3-18 years old with sickle cell disease. Sixty patients were evaluated, with a mean age of 10.80 + 4.21 years. The prevalence of vitamin D deficiency was 46.7% (21.02 ± 8.47 ng/mL). Patients were clustered into two groups regarding vitamin D deficiency (25-OH-D < 20 ng/mL). When comparing groups with and without vitamin D deficiency, age (p = 0.002) and season of 25-OH-D collection (p = 0.005) were statistically significant. Age presented OR 1.23 (95% CI: 1.07; 1.41/p = 0.004), as well as the season of the 25-OH-D collection with OR 5.21 (95% CI: 1.58; 17.14/p = 0.007) for autumn/winter assessment. After linear regression, an association was noted for age (β = -0.80/95% CI: -1.29; -0.320/p = 0.002), days of sun exposure (β = 0.83/95% CI: 0.07; 1.58/p = 0.032), and autumn/winter vitamin D assessment (β = -7.94/95% CI: -12.02; -3.85/p = 0.032). In conclusion, hypovitaminosis D is highly prevalent in this population; meanwhile, age, season of 25-OH-D collection, and days of sunlight exposure appeared as risk factors for deficiency.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"92-103"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Tolerability of a 3-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients: Results of an Open-Label, Single-Arm Phase 4 Trial. 一项开放标签、单组4期试验的结果：3天福沙吡坦方案预防儿科患者化疗引起的恶心和呕吐的安全性和耐受性

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2025-03-01 Epub Date: 2024-12-10 DOI: 10.1080/08880018.2024.2437047

Juan Luis Garcia Leon, Cara DiCristina, Ruji Yao, Amna Sadaf Afzal

{"title":"Safety and Tolerability of a 3-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients: Results of an Open-Label, Single-Arm Phase 4 Trial.","authors":"Juan Luis Garcia Leon, Cara DiCristina, Ruji Yao, Amna Sadaf Afzal","doi":"10.1080/08880018.2024.2437047","DOIUrl":"10.1080/08880018.2024.2437047","url":null,"abstract":"Convenient multiday dosing of antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting (CINV) are needed in pediatric patients, who are more likely than adults to be treated with emetogenic chemotherapy over multiple consecutive days. Intravenous (IV) fosaprepitant is approved for the prevention of CINV in children aged 6 months and older. This open-label, single-arm study assessed the safety and tolerability of a 3-day fosaprepitant regimen (consecutive daily IV administration on days 1-3) plus a serotonin receptor antagonist with or without dexamethasone in pediatric patients (6 months to 17 years) receiving emetogenic chemotherapy. Study treatment was initiated at the start of a chemotherapy cycle (cycle 1); patients completing cycle 1 could participate in optional cycles 2 and 3. Primary endpoints included adverse events (AEs) and AE-related discontinuation during cycle 1.98/100. Patients completed cycle 1; 69 participated in optional cycles 2 and 3. The AE profile during cycle 1 was typical of cancer patients receiving emetogenic chemotherapy; 80/100 (80.0%) patients experienced ≥1 AE. AE rates were generally similar between patients aged 6 months to <2 years (11/15 patients [73.3%]), 2 to <6 years (22/30 [73.3%]), 6 to <12 years (24/25 [96.0%]), and 12-17 years (23/30 [76.7%]). Rates of drug-related AEs (4/100 [4.0%]) and AE-related discontinuations (2/100 [2.0%]) were low. Similar trends in safety outcomes were observed during cycles 2 and 3. No deaths were reported. The 3-day IV fosaprepitant regimen for the prevention of CINV was generally well tolerated in pediatric patients receiving emetogenic chemotherapy.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"79-91"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case control analysis of pattern and risk factors for pulmonary dysfunction amongst childhood cancer survivors: a single centre study from a low-middle income setting.

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-07 DOI: 10.1080/08880018.2025.2456934

Payal Malhotra, Sandeep Jain, Rahul Sharma, Anjali Pahuja, Rajiv Goyal, Anurag Sharma, Gauri Kapoor

{"title":"A case control analysis of pattern and risk factors for pulmonary dysfunction amongst childhood cancer survivors: a single centre study from a low-middle income setting.","authors":"Payal Malhotra, Sandeep Jain, Rahul Sharma, Anjali Pahuja, Rajiv Goyal, Anurag Sharma, Gauri Kapoor","doi":"10.1080/08880018.2025.2456934","DOIUrl":"10.1080/08880018.2025.2456934","url":null,"abstract":"Pulmonary toxicity is one of the most common morbidities experienced by childhood cancer survivors (CCS). The aim of this study was to identify prevalence, pattern of dysfunction, and risk factors among CCS and compare with age and sex matched controls. Details of demographic and pulmonary-toxic treatment of CCS at least 2 years off-treatment were collected and a cross-sectional analysis of pulmonary function test (PFT) and risk factors was performed. Spirometry findings were categorized as normal, restrictive, or obstructive and diffusing capacity of carbon monoxide (DLCO) as normal or abnormal. PFT data of 192 CCS and 50 controls was analyzed. One or more abnormalities inspirometry or DLCO were observed among 112 (58.3%) CCS and 8 (16%) controls (p value <0.01). Abnormal PFT was more likely to be associated with older age at evaluation, longer follow-up, and use of chest-directed radiotherapy (p value 0.002, 0.02, 0.03). DLCO was the most common abnormality observed in 85 (44%) patients. Obstructive and restrictive patterns were observed in 66 (34.3%) and 42 (21.8%) survivors respectively. There was no correlation between any risk factor and specific pattern of pulmonary dysfunction. On univariate analysis age at evaluation >20 years, follow-up >10 years, cumulative bleomycin more than 120 mg/m2, chest-directed radiotherapy, surgery, and female gender were found to be predictive for abnormal PFT. On multivariable analysis first four factors retained significance. High subclinical prevalence among CCS especially in older patients with longer follow-up mandates longitudinal follow-up to assess long-term pulmonary outcome and plan intervention strategies for this subset.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"104-114"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative analysis of a novel next-generation sequencing-based IGH clonality assay for measurable residual disease detection in pediatric B-cell acute lymphoblastic leukemia patients.

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-13 DOI: 10.1080/08880018.2025.2463927

Min-Seung Park, Hee Young Ju, Ji Won Lee, Keon Hee Yoo, Hee-Jin Kim, Duck Cho, Hyun-Young Kim

{"title":"Comparative analysis of a novel next-generation sequencing-based IGH clonality assay for measurable residual disease detection in pediatric B-cell acute lymphoblastic leukemia patients.","authors":"Min-Seung Park, Hee Young Ju, Ji Won Lee, Keon Hee Yoo, Hee-Jin Kim, Duck Cho, Hyun-Young Kim","doi":"10.1080/08880018.2025.2463927","DOIUrl":"10.1080/08880018.2025.2463927","url":null,"abstract":"Measurable residual disease (MRD) is critical in guiding therapeutic strategies for B-cell acute lymphoblastic leukemia (B-ALL). This study evaluated the performance of a novel next-generation sequencing-based Celemics IGH assay (CM-IGH; Celemics, Seoul, Korea) compared with the LymphoTrack® IGH FR1 assay (LT-IGH; Invivoscribe Technologies, USA) and multiparameter flow cytometry (MFC). A total of 31 diagnostic and 60 follow-up bone marrow aspirate samples, all from the same 31 pediatric patients with B-ALL, were analyzed using the CM-IGH and LT-IGH assays on the MiSeq platform, as well as MFC according to EuroFlow guidelines. Initial IGH clonality was detected in 83.9% of CM-IGH samples and 90.3% of LT-IGH samples (p = 0.060). MRD positivity rates in follow-up samples were 74.5% for CM-IGH, 61.1% for LT-IGH, and 56.7% for MFC. CM-IGH showed concordance rates of 78.3% with LT-IGH and 68.1% with MFC, while LT-IGH demonstrated an 81.5% concordance rate with MFC. The correlation coefficients (r) of MRD levels were 0.831 between CM-IGH and LT-IGH, 0.702 between CM-IGH and MFC, and 0.776 between LT-IGH and MFC. The CM-IGH assay demonstrates substantial concordance with LT-IGH and MFC in detecting MRD in pediatric patients with B-ALL, highlighting the complementary value of IGH clonality assays and MFC.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"115-125"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143409624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The prevalence of opioid misuse diagnostic codes in children with sickle cell disease. 镰状细胞病儿童阿片类药物滥用诊断代码的患病率

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2025-03-01 Epub Date: 2024-12-11 DOI: 10.1080/08880018.2024.2437045

Ann-Marie Tantoco, Sherif M Badawy, Cheryl K Lee, Jeffrey Merz, Maura Steed, Mark Kluk, Ajay Bhasin

{"title":"The prevalence of opioid misuse diagnostic codes in children with sickle cell disease.","authors":"Ann-Marie Tantoco, Sherif M Badawy, Cheryl K Lee, Jeffrey Merz, Maura Steed, Mark Kluk, Ajay Bhasin","doi":"10.1080/08880018.2024.2437045","DOIUrl":"10.1080/08880018.2024.2437045","url":null,"abstract":"Hospitalized patients with sickle cell disease (SCD) may use opioid medications for both acute and chronic pain management. Use of these medications may unintentionally generate diagnostic codes for opioid misuse including \"opioid use,\" \"opioid abuse,\" and \"opioid dependence,\" which connote a behavioral problem or addiction. In this study, we sought to compare diagnostic codes for opioid misuse amongst hospitalized patients with and without SCD. We performed a cross-sectional study of hospitalized non-obstetric, non-surgical, and non-elective patients with SCD using the National Inpatient Sample published by the Agency for Healthcare Research and Quality Hospital Cost Utilization Project during years 2016-2019. We used descriptive statistics to characterize patient demographics and opioid misuse diagnostic codes. We used Chi Square testing to compare rates of diagnostic codes for opioid misuse between patients with and without SCD. There were 165 ± 3 hospitalizations for SCD per 100,000 US population. Patients with SCD had higher rates of opioid misuse diagnostic codes for \"opioid use\" (0.3% vs 0.1%, p < 0.001) and \"opioid dependence\" (4.5% vs 1.6%, p < 0.001), but a lower rate for \"opioid abuse\" (0.2% vs 0.3%, p < 0.001). We found that diagnostic codes for opioid misuse are higher in those with SCD than without SCD, even at young ages, which impart substantial bias toward these patients.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"69-78"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0